NEW YORK (GenomeWeb News) — Molecular diagnostic developer Immunexpress has garnered $6 million in financing led by Switzerland's Debiopharm Group, the companies said today.

Immunexpress, which has locations in Brisbane, Australia, and Seattle, said it will use the funding to advance development of its SeptiCyte technology and to bring one of its late-stage sepsis diagnostic products to market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.